Physicians (ACCME)

The MEKtrix: Advancing Neurofibromatosis Type 1 Care Across the Lifespan

Neurofibromatosis Type 1 (NF1) requires a nuanced clinical approach due to its diverse neuro-oncologic manifestations and potential for significant morbidity. To facilitate timely diagnosis and intervention, health care professionals must recognize early neurologic signs and tumor…

Livestream: The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…

The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…

Maintaining Patient QoL through Optimal Management of ADC-Associated AEs

Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…

Clinical Trial Data with ADCs: New Options for HER2-Negative MBC

The rapidly shifting therapeutic landscape for HER2-negative metastatic breast cancer (MBC) challenges clinicians to stay up-to-date on emerging clinical trial data, as well as recommendations on therapy selection and sequencing. Unfamiliarity with antibody-drug conjugate (ADC) treatment…

ADCs and Chemotherapy: More Different Than You Might Expect in HER2-Negative MBC

Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody directed against a tumor-associated antigen. Conjugation fundamentally alters tissue…

Emerging Considerations for the Role of Biomarker-Driven Immunotherapy in Upper GI Cancers

Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians…

Advancing Cervical Cancer Care: Navigating New Therapies, Guidelines, and Patient-Centric Approaches

Delayed diagnosis of cervical cancer often leads to poor prognosis and lower survival rates, especially in advanced stages. Recent therapeutic advancements, including immune-checkpoint inhibitors and antibody-drug conjugates (ADCs), offer new hope for managing advanced cervical cancer….

MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-world Applications in NF1-PN Management

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively…

The Promise of Folate Receptor Alpha-Targeting ADCs for Platinum-Resistant Ovarian Cancer

Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…